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Abstract 
Objective 
Patients admitted with acute variceal bleeding (AVB) and Child Pugh C score (CP-C) or Child Pugh B 
plus active bleeding at endoscopy (CP-B+AB) are at high risk for treatment failure, rebleeding and 
mortality. Preemptive TIPS (p-TIPS) has been shown to improve survival in these patients but its use 
in clinical practice has been challenged and not routinely incorporated. The present study aimed to 
further validate the role of preemptive TIPS in a large number of high-risk patients. 
Design 
Multicenter, international, observational study including 671 patients from 34 centers admitted for 
AVB and high-risk of treatment failure. Patients were managed according to current guidelines and 
use of drugs and endoscopic therapy (D+E) or preemptive TIPS (p-TIPS) was based on individual 
center policy.  
Results 
p-TIPS in the setting of AVB is associated with a lower mortality in Child C patients compared to D+E 
(1 year mortality 22% vs 47% in D+E group; P=0.002). Mortality rate in CP-B+AB patients was low and 
p-TIPS did not improve it. In CP-C and CP-B +AB patients, p-TIPS reduces treatment failure and 
rebleeding (1 year CIF-probability of remaining free of the composite endpoint: 92% vs 74% in the 
D+E group; P=0.017), development of “de novo” or worsening of previous ascites without increasing 
rates of hepatic encephalopathy  
Conclusion  
p-TIPS must be the treatment of choice in CP-C patients with AVB.  Due to the strong benefit in 
preventing further bleeding and ascites, p-TIPS could be a good treatment strategy for CP-B+AB 
patients. 
 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Introduction 
AVB remains the most severe and life-threatening complication of portal hypertension in patients 
with cirrhosis. The better understanding of AVB pathophysiology has led in the last decades to a 
significant improvement in its management and a reduction in mortality rates. However, despite 
applying the gold-standard therapy, 10-15% patients with AVB experience treatment failure, 21% re-
bleed and 24% die during the first 6 weeks(1). Moreover, there is a subgroup of patients with AVB 
with worse prognosis in which re-bleeding is as high as 50% during the first year and mortality 
reaches 40%(2). Numerous efforts have been conducted to identify factors associated with this poor 
outcome that may help to select patients that might benefit from a more aggressive management. 
The Child-Pugh (CP) classification, aspartate aminotransferase levels, shock on admission, presence 
of portal vein thrombosis, presence of hepatocellular carcinoma, active bleeding at endoscopy on 
admission, hepatic venous pressure gradient (HVPG) >20 mmHg and a MELD-based score have been 
identified as predictors of poor outcome in patients with cirrhosis and AVB(3-9). In this subgroup of 
high-risk patients, several studies have shown that placement of TIPS (Transjugular intrahepatic 
portosystemic shunt) within 72 hours from admission before uncontrolled bleeding or rebleeding 
occurs (called early or p- TIPS) is effective in preventing treatment failure and rebleeding (2, 10, 11) 
(9) without increasing either hepatic encephalopathy (HE) rate or other adverse events. In addition, 
of these studies (two randomized controlled trials and one observational) also demonstrated that 
the p-TIPS strategy increases survival (2, 10). Despite all this evidence and probably due to the 
relatively small number of patients included in all these studies implementation of p-TIPS in real-life 
clinical practice has been defied. Indeed, a recently published paper (12) evaluate real life results in 
58 centers in France (including academic and non-academic center) an only 6.7% of the high-risk 
patients included were treated with p-TIPS, underscoring the lack of adherence of physicians in a 
real-life setting.  
We aimed to conduct a large multicenter international observational study in patients with cirrhosis 
and a high-risk AVB admitted to several centers worldwide, with the main aim to corroborate if the 
use of p-TIPS improves the outcome of these patients and therefore should be more rigorously 
included in clinical practice.  
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Methods 
Study design and patients  
We performed a multicenter, international, observational study in 33 referral centers in Europe & 
one center in Canada, between October 2011 and May 2015. All the 34 centers collected data 
prospectively from all patients with cirrhosis admitted for AVB from October 2013 to May 2015. In 
addition, patients that were prospectively registered since October 2011 in 19 of the 34 centers that 
already had preexisting databases/registers of all patients with AVB admitted to their hospitals, 
were also included. All patients were managed according to current guidelines (Baveno V consensus 
and AASLD guidelines). All consecutive patients admitted to the participating centers with a portal 
hypertension related bleeding were included in the database of the study regardless the severity of 
the hemorrhage and/or the presence of high-risk criteria. Patients were asked to sign an informed 
consent to be registered and for the use of their clinical data. A total of 2138 patients were 
consecutively registered in the database.  For this study, from the whole sample registered, only 
data from high-risk patients were analyzed. Although MELD score has been appointed as a 
prognostic factor in the setting of AVB (13), we started the study before publication of the paper 
demonstrating the value of the modified MELD. Moreover, centers performing p-TIPS selected high-
risk patients based on Child C < 14 points and Child B plus active bleeding at initial endoscopy. Only 
45 patients from all the participating centers did not give informed consent to use their clinical data 
and therefore were not registered in the database. 
Exclusion criteria were: age older than 75 years, pregnancy, hepatocellular carcinoma outside the 
Milan criteria, a creatinine level greater than 3 mg per deciliter (265 μmol per liter), a Child–Pugh 
score above 13 points, active sepsis, heart failure and total portal-vein thrombosis. Due to the 
observational nature of the study, decision of placing p-TIPS or using drug plus endoscopic therapy 
in patients with a high-risk AVB was based on the internal hospital policy and the treating physician’s 
opinion regardless our study. Only 9 centers from the 34 participating had incorporated p-TIPS in 
their daily clinical management algorithm;  4 of them were also involved in the previous trials (2, 10) 
and 5 incorporated the p-strategy once the current study have already began (Suppl. Table 1) 
 All patients were initially treated with standard of care treatment (vasoactive drugs, antibiotic and 
endoscopic treatment). Afterwards, patients continued on vasoactive drugs until a 
polytetrafluoroethylene (PTFE)-covered TIPS was performed within 72 hours after diagnostic 
endoscopy (p-TIPS group) and or were kept on vasoactive drugs (D+E group) until secondary 
prophylaxis was started and PTFE-TIPS was only used as a rescue treatment. 
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The primary end point of the study was survival at 6 weeks and 1 year.  
Secondary endpoints were: 1) the composite endpoint of failure to control acute bleeding (up to day 
5), early rebleeding (from day 5 to day 42) and late rebleeding (from day 42); 2) onset or worsening 
of ascites (defined as need of large volume paracentesis or permanent/significant increase in 
diuretic dose without complete ascites disappearance); 3) development of hepatic encephalopathy.  
Hepatic encephalopathy (HE) was diagnosed following the American Association for the Study of 
Liver Diseases (AASLD) and the European Association for the Study of the Liver Practice Guidelines 
(14). Only clinical HE was considered for the study and grade of HE I-IV was defined according to the 
severity of manifestations. Ascites and ascites-related complications (spontaneous bacterial 
peritonitis & Hepatorenal syndrome) were defined and graded according to the AASLD Practice 
Guidelines (15)   
Patients were followed up to 12 months or until death or liver transplantation and clinical 
information during this period was used for the analysis.  
 
Data collection 
The ethics committees of all participating hospitals approved the study protocol. All data were 
gathered in the context of standard practice from the clinical records of the patients, encrypted, 
collected and managed using REDCap electronic data capture tools hosted at Hospital Santa Creu i 
Sant Pau (Barcelona). REDCap (Research Electronic Data Capture) is a secure, web-based application 
designed to support data capture for research studies, providing 1) an intuitive interface for 
validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) 
automated export procedures for seamless data downloads to common statistical packages; and 4) 
procedures for importing data from external sources(16). A steering committee was created in order 
to regularly monitor data to detect inconsistencies or errors; when find, queries requiring resolution 
by the local investigators were sent to each center. All reported clinical variables were finally 
validated by the steering committee before the statistical analysis of the data.  
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Statistical Analysis 
The study followed the Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) guideline for reporting observational studies(17). Data were described as frequencies and 
percentages, means and standard deviation (SD) or median (interquartile range), as appropriate. 
Baseline characteristics were compared using the Fisher’s exact test for categorical variables, the t-
test for Gaussian continuous variables and the Mann-Whitney for ordinal and non-Gaussian 
continuous variables. Survival was estimated using the cumulative incidence function (CIF) with 
orthotropic liver transplant (OLT) as a competing risk. The risk (Hazard ratio and 95%CI) of death was 
evaluated using a competitive risk Cox model. The secondary time to event variables were evaluated 
likewise, but with both death and OLT as a competing risk. Adjusted models were built using 
propensity scores (PS, i.e. the predicted probability of p-TIPS or the reason for p-TIPS placement) 
given a set of baseline covariates. All reported analyses for time to event variables are based on 
competitive risk models and all the inferential analyses are PS adjusted, or otherwise specified. 
All the analyses were performed using SAS software (9.2; SAS Institute Inc., Cary, NC) or Statistical 
Package for Social Sciences (version 19.0; SPSS, Chicago, IL), and a level of significance was 
established at the two-sided 5% level.  
 
Results:  
From October 2013 to May 2015, the 34 centers participating in the observational study 
prospectively collected data from 1334 patients with cirrhosis admitted for AVB.  Further, additional 
804 patients prospectively registered from October 2011 to September 2013 in the 19 of these 
centers with pre-existing prospective database/registers were also included. Thus a total of 2138 
patients with AVB were registered in the REDCap database and 927 (43%) of them met the defined 
high-risk criteria (CP-C and CP-B+AB). As shown in Suppl Figure 1, 256 patients had one or more 
exclusion criteria. Consequently 671 patients were included in the main analysis (434 CP-C and 237 
CP-B+AB); 605 patients (90%) belonged to the D+E group and 66 (10%) to the p-TIPS group.  There 
were no major differences in baseline characteristics between the two groups (Table 1).  
211 (31.4%) patients in the whole cohort were lost during the 1 year follow up, 89 (37.6%) in the CP-
B+AB and 122 (28.1%) in the CP-C. When considered 42 days follow up, 78 patients (11.6%) were lost 
to follow up, 21 patients (8.8%) in the CP-B+AB group and 53 patients (12.2%) in the CP-C group.  
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Survival 
P-TIPS markedly improved survival in the whole cohort of high-risk patients admitted with AVB: 6 
weeks: 92% vs 77%; 1 year: 78% vs 62%; P=0.014 (Figure 1A). To assess whether CP-C and CP-B+AB 
patients equally benefits from the p-TIPS placement, we evaluated both subgroups separately. CP-C 
patients treated with p-TIPS had a significantly higher survival than the D+E group (6w 90% vs 70%: 1 
y: 78% vs 53%; Figure 1C; P=0.002). Mortality rate in the subgroup CP-B+AB was low and not 
significantly different in the D+E and in the p-TIPS group (6 w: 94% vs 90%; 1 y: 77% vs 75%; P=0.935) 
(Figure 1B).  
We also calculated the probability of death at 6 weeks by using the MELD-based model due to its 
demonstrated ability to predict mortality (13). To calculate the observed mortality, we grouped the 
study population by using quintiles of the observed MELD. The results are plotted in Figure 2. The 
analysis of lineal correlation was r=0.999 (p<0.001) for Drug+Endo group confirming that the 
mortality observed in our study was similar to the one predicted by the MELD-based model. 
However, the p-TIPS group had lower mortality that predicted for any given MELD value (lineal 
correlation r=0.758 (p=0.137)), confirming the benefit of the p-TIPS strategy. 
To estimate the adjusted effect of p-TIPS accounting for the covariates that were predictors of 
receiving the treatment, we first estimated that probability (i.e. propensity scores) fitting a logistic 
regression model, and then we include that probability as a covariate in the survival models (Table 2 
and Supplementary Table 1). Results shown in table 2 confirm that the benefit in survival depended 
on the placement of p-TIPS. 
The number of patients needed to be treated [95%CI] to save one live during 1 year estimated using 
PS-adjusted competing risk was 4.2 [2,6-24,4].  
A total of 224 patients (33.4%) died; 212 (35%) patients in the D+E group died as compared with 12 
(18%) in the p-TIPS group. Nineteen, 19 (4.9%), patients in the D+E group received OLT vs 6 (12.8%) 
in the p-TIPS group. Causes of death are represented in Table 3.  
Despite having incorporated routinely the p-TIPS strategy, 92 patients (from the 9 p-TIPS centers) did 
not receive p-TIPS due to unavailability, a few “non-believers” physicians and in 5 of the centers the 
delay in routinely adopting the p-TIPS strategy. Although PS robustly guarantee that the two groups 
analyzed were comparable to further discard a selection bias effect, we analyzed survival-comparing 
patients who did not receive TIPS in the p-TIPS centers with the patients treated in the non p-TIPS 
centers. As seen in Suppl Fig 3, patients not managed with p-TIPS had similar outcome regardless 
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their management in p-TIPS or non p-TIPS centers, corroborating the bad outcome of our high risk 
population.  
 
Composite endpoint of failure to control bleeding & preventing rebleeding 
In the D+E group 141 (23.3%) patients had failure to control bleeding or rebleeding vs 3 (4.5%) in the 
p-TIPS group and 44 (7%) patients in the D+E group required rescue TIPS (Table 3). When considering 
death or OLT as competing risk events, the PS-adjusted risk of achieving the composite endpoint was 
markedly reduced in the p-TIPS vs the D+E group (HR: 0.17; CI 95%: 0.05-0.53, Figure 3A; P=0.002) 
(Figure 3A). Failure to control bleeding or rebleeding was significantly lower in the p-TIPS group 
either in the CP-B+AB or in the CP-C patients (Figure 3B and C). In the unadjusted analysis, the 
benefit of p-TIPS on the composite endpoint remained (Table 2). 
 
De novo or Worsening Ascites  
In the D+E group 288 (47.6%) patients had “de novo” or worsening of previous ascites vs 6 (9.1%) in 
the p-TIPS group (Table 3). Regarding ascites-related complications, 99 (16.3%) patients in the D+E 
group developed spontaneous bacterial peritonitis or hepatorenal syndrome vs 1 (1.5%) in the p-
TIPS group. The 1-year risk of “de novo” or worsening ascites considering death as a competing risk 
event was dramatically reduced in the p-TIPS group for the PS-adjusted analysis (HR: 0.16; (CI 95%: 
0.07-0.35); Figure 4A: P<0.001). The marked benefit of p-TIPS over ascites was observed both in CP-
B+AB and CP-C patients (Figure 4B and 4C) and observed in the unadjusted analysis (Table 2). 
 
Hepatic encephalopathy (HE)  
228 (37.7%) patients had any episode of HE in the D+E group vs 28 (42.4%) in the p-TIPS group (Table 
3). The risk of developing any grade of hepatic encephalopathy considering death or OLT as 
competing risk events was similar between groups for the PS-adjusted analysis (HR 1; CI 95%: 0.73-
1.45); Figure 5: P=0.863). There were no differences between groups and the similar rate of HE was 
observed both in CP-B+AB and CP-C patients (Figure 5B and 5C). In the unadjusted analysis, the 
results were consistently similar (Table 2). 
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Discussion  
Previous studies have demonstrated that treating patients at high risk of treatment failure placing a 
p-TIPS (also call early TIPS) within 72 hours from admission before uncontrolled bleeding or re-
bleeding occurs, improves outcome. Precisely, all the data available have shown that this strategy is 
associated with a reduction in failure, rebleeding and development of  “de novo “or worsening of 
ascites (9) (2) (10) (11). In addition, all the studies but one(11), also demonstrated a clear benefit for 
p-TIPS on survival. However, despite all this strong evidence, implementation of p-TIPS has not been 
widely accepted. As confirmed with this study, only 13% of high-risk patients admitted to centers 
participating in the study received p-TIPS. It is also noticeable that not all high-risk patients admitted 
with AVB may benefit from p-TIPS; indeed in our study 256 (27.6%) of them had at least one-
exclusion criteria. However from the 671 patients without any contraindication, only 66 (13%) 
received p-TIPS. This is in agreement with a recent multicentric study performed in France (12) also 
confirms this data and from 326 eligible only 22 (6.7%) of them received p-TIPS, underscoring the 
lack of adherence of physicians in a real-life setting. When specifically evaluated, the main reasons 
are either that treating physicians do not believe in p-TIPS benefit or the lack of availability of the 
technique. The first limitation could be overcome carefully analyzing these and previous data 
showing that patients not receiving TIPS regardless of the expertise and/or availability of the center 
where they are managed have a higher mortality  rate than patients receiving p-TIPS. Remarkably, 
the number of patients needed to be treated to save one live is 4. This mean that if all 671 patients  
had been treated with p-TIPS, the number of death could have been reduced significantly from 224 
to 65 and we could have saved 159 deaths.  
The second one should be focused on programs aimed at easily transferring patients to centers of 
expertise. As recently demonstrated(18) centers placing more than 20 TIPS per year have the best 
outcome possible and  lower in-patient mortality, therefor efforts aimed to better equip high 
volume institutions should be implemented.  Therefore, in centers with no access to TIPS placement, 
the policy to be adopted will be to transfer patients to centers of expertise instead of trying to 
implement it.  It is also of note that other diseases with similar mortality rates and successful 
treatments able to improve survival such as stroke and heart attack, have motivated changes in the 
sanitary policy worldwide with the main aim to treat patients as soon as possible in centers of 
expertise.  
Based on this results, all the efforts directed to implemented and guarantee the access to p-TIPS 
treatment are widely justify.  
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Other potential reason may have been the fear for the high rate of HE and TIPS dysfunction reported 
in previous studies using TIPS as a salvage therapy for refractory bleeding and using bare stents (19) 
(20) (21). However, none of the studies evaluating the role of p-TIPS increased HE (9) (2) (10) (11) 
and the rate of TIPS dysfunctions reported using covered stents is very low(2) (10) (11).  
To overcome these limitations we decided to run an observational study in centers with expertise in 
the management of AVB to evaluate the efficacy of p-TIPS. With this aim, we collected all the 
consecutive portal hypertension related bleeding episodes in the participating centers and analyze 
the outcome only in those patients fulfilling the previously identified high-risk criteria. The decision 
of placing a p-TIPS was based on the internal hospital policy and the treating physician’s opinion, 
regardless our study. 
Our study, including a large number of patients (671) with high-risk criteria admitted for AVB clearly 
confirms that the use of p-TIPS reduces failure to control bleeding and rebleeding, reduces “de 
novo” or worsening in the control of ascites, did not increase hepatic encephalopathy and improves 
survival.  
We also evaluate whether the use of p-TIPS equally benefits CP-B+AB and CP-C patients. The All the 
benefits of p-TIPS, but improvement in survival, were homogeneously found either in Child C or in 
CP-B+AB patients. P-TIPS was not able to have a significant impact in CP-B+AB survival, probably due 
to the low mortality rate observed in CP-B+AB patients (19%) that makes difficult to demonstrate a 
potential effect on survival without evaluating a very large number of patients. Despite the lack of 
benefit on survival, the better control of further rebleeding and ascites without increasing the risk or 
severity of hepatic encephalopathy, could justify the use of p-TIPS in this subgroup of patients. 
Our study proves that tailoring treatment to patient‘s risk is a real option in the setting of AVB. Child-
Pugh classification together with endoscopic findings simply identify early after admission patients in 
who p-TIPS improves outcome. These criteria are easy to apply in daily clinical practice but the 
accuracy and reproducibility of these parameters face some difficulties. On one hand performing 
endoscopy in bleeding patients and identifying active bleeding can be challenging. On the other 
hand, some components of the Child-Pugh classification have subjectivity and the limitation of 
having albumin determined at admission. Although other predictive factors have been shown to 
robustly predict outcome in the AVB scenario such as de modified MELD model (8), we decided to 
use CP-C and CP-B+AB as they were the criteria used to determine high-risk by the participating 
centers. However the high-risk mortality of our cohort was confirmed when using the MELD-based 
model and mortality observed in the population not treated with p-TIPS was as high as the one 
predicted by the modified model. Nevertheless it is possible that more objective and reproducible 
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predictive factors may still be identified that could perhaps improve the selection of patients that 
may benefit from p-TIPS. It is also important to remark that our results cannot be extrapolated to 
aged patients, patients with deteriorated kidney function (creatinine >3mg/dl), occlusive PVT, sepsis, 
heart failure or hepatocellular carcinoma out of the Milan criteria as this population was neither 
include in our study nor in the previous ones.  
The main limitation of our study comes from its observational design that carries an inherent risk of 
selection bias, however the use of propensity score precisely lowers this possibility. Another 
potential limitation of our study may be the lower than expected number of patients treated with p-
TIPS. Aiming at including a large sample size, the study was performed in 34 centers altogether 
collecting a large number of high-risk patients (671), Nonetheless we did not reach a very high 
number of p-TIPS probably because of a low rate of p-TIPS indicated by treating physicians. Even 
with these limitations, this study allowed us obtaining robust data that corroborates previous 
evidence.  
 
Conclusions 
In conclusion, the use of p-TIPS with an e-PTFE–covered stent increases survival in Child-Pugh C 
patients admitted with AVB. In CP-C and CP-B+AB p-TIPS decreases failure to control bleeding, 
rebleeding, “de novo” ascites development or worsening, without increasing the risk of developing 
hepatic encephalopathy.  These results strongly support the view that p-TIPS must be the treatment 
of choice in CP-C patients with AVB. Due to the strong benefit in preventing further bleeding 
episodes and ascites without increasing HE p-TIPS could be recommended for CP-B+AB patients.  
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Table 1. Baseline characteristics  
 
Characteristic 
 
Endo+Drug 
Group 
(N=605) 
Preemptive-TIPS 
Group 
(N=66) 
P Value 
Age 54.5 ±9.7 52.4 ±11.2 0.128 
Gender: male n(%) 466 (77.0%) 47 (71.2%) 0.335 
Etiology of cirrhosis* 
   
Alcohol 457 (75.5%) 55 (83.3%) 0.174 
Viral 187 (30.9%) 15 (22.7%) 0.201 
Other 76 (12.6%) 4 (6.1%) 0.161 
Active alcoholism (last 3 m) 326 (55.5%) 34 (52.3%) 0.692 
Charlson Comorbidity Index 
Mean (SD) 
4.561 (1.326) 4.709 (1.51) 0-623 
Previous Bleeding 
   
Child B 80 (36.7%) 6 (31.6%) 0.656 
Child C 110 (28.4%) 11 (23.4%) 0.469 
MELD Score 15.5 ±7.2 15.2 ±5.7 0.668 
Child-Pugh Score 9.9 ±1.8 10.1±1.5 0.446 
Child-Pugh C (n) 387 (64.0%) 47 (71.2%) 
0.242 
Child-Pugh B + Active bleeding 218 (36.0%) 19 (28.8%) 
Descriptive data are mean±SD and n (%) 
*More than one answer is possible 
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Table 2.Risk of mortality, rebleeding, ascites and encephalopathy using competitive risk approaches for the whole high-risk cohort and the Child-B+AB and  
Child-C groups. 
 Child 
Raw analysis 
Propensity score*  
adjusted analysis 
p-value HR [IC 95%] p-value HR [IC 95%] 
Mortality 
 High-Risk 0.0087 0.480 [0.273 to 0.844] 0.0141 0.491 [0.278 to 0.867] 
Child-B+AB 0.9585 0.966 [0.303 to 3.082] 0.9348 0.953 [0.298 to 3.045] 
Child-C 0.0013 0.366 [0.192 to 0.699] 0.0023 0.363 [0.189 to 0.696] 
Failure to control bleeding & rebleeding 
 High-Risk 0.0004 0.176 [0.057 to 0.542] 0.0022 0.170 [0.055 to 0.53] 
Child-B+AB 0.0286 NE NE NE 
Child-C 0.0055 0.241 [0.078 to 0.743] 0.0175 0.251 [0.08 to 0.785] 
Ascites 
 High-Risk <.001 0.170 [0.078 to 0.37] <.001 0.161 [0.073 to 0.353] 
Child-B+AB 0.0006 NE NE NE 
Child-C <.001 0.225 [0.104 to 0.488] <.001 0.227 [0.105 to 0.494] 
Encephalopathy 
 High-Risk 0.4477 1.146 [0.823 to 1.597] 0.8634 1.031 [0.731 to 1.452] 
Child-B+AB 0.8777 0.925 [0.353 to 2.421] 0.9240 0.954 [0.363 to 2.505] 
Child-C 0.579 1.116 [0.792 to 1.572] 0.7832 1.051 [0.739 to 1.494] 
Sample sizes for Endo+Drug and Early Tips are 605 vs 66 in the overall high-risk cohort, 218 vs 19 in the Child B+AB group and 387 vs 47 in the Child C group. 
Endo+Drug is the reference category for the risk calculation 
p-values from the Fine-Gray test (raw analysis) or the competitive Cox model (PS adjusted analyses) 
NE: not estimable 
*: Propensity scores model for all high-risk patients included age, Child-Pugh and bilirubin; for the Child-B+AB group: age, Albumin and INR and for the Child-C group: bilirubin. 
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Table 3. Summary of Efficacy Measurement 
Variable 
Endo+Drug Group 
(N=605) 
Preemptive-TIPS Group 
(N=66) 
Child C (no. of patients) 387 47 
Child B+AB (no. of patients) 218 19 
Composite Endpoint (no. of 
patients) 
  
Child B+AB 50 (22.9%) 0 (0.0%) 
Child C 91 (23.5%) 3 (6.4%) 
Rescue TIPS   
Child B+AB 20 (9.2%) 0 (0.0%) 
Child C 24 (6.2%) 0 (0.0%) 
Death (no. of patients)   
Child B+AB 43 (19.7%) 3 (15.8%) 
Child C 169 (43.7%) 9 (19.1%) 
Cause of death   
Bleeding 34 (16.0%) 0 (0.0%) 
Liver failure 80 (37.7%) 1 (8.3%) 
Sepsis/multiorganic failure 66 (31.1%) 8 (66.7%) 
Unknown 6 (2.8%) 1 (8.3%) 
Other 26 (12.3%) 2 (16.7%) 
Orthotropic liver transplantation   
Child B+AB 1 ( 0.5%) 1 ( 5.3%) 
Child C 19 ( 4.9%) 6 ( 12.8%) 
Hepatic encephalopathy   
Child B+AB 55 ( 25.2%) 4 ( 21.1%) 
Child C 173 ( 44.7%) 24 ( 51.1%) 
Ascites   
Child B+AB 96 ( 44.0%) 0 ( 0.0%) 
Child C 192 ( 49.6%) 6 ( 12.8%) 
Spontaneous Bacterial Peritonitis/ 
Hepato-renal Syndrome 
  
Child B+AB 19 (8.7%) 0 ( 0.0%) 
Child C 80 (20.7%) 1 (2.1%) 
* Percentages calculated from the total number of Child B+AB or Child C patients 
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